KLK3 and prostate cancer: Our hypothesis is that, due to the low reported α/β ratio for prostate cancer, the hypofractionated regimen delivered with SBRT, should produce a more substantial PSA response than CF-EBRT, as reflected in a greater rate of PSA decline and a lower PSA nadir.